- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT02342574
F901318 Multiple Ascending Dose Study
F901318 - A Phase I, Double-Blind, Placebo Controlled, Single and Multiple Ascending Intravenous Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects
연구 개요
상세 설명
Double blind, placebo controlled, ascending single and multiple intravenous dose, sequential group study. This will be a study in two parts. In the first part, up to twenty four subjects will complete the study in up to 3 cohorts (Groups A to C), each group consisting of 8 subjects, six of whom will receive active compound and two will receive placebo for eight days. Each subject will be on study for approximately 7 weeks. Each subject will participate in one treatment cohort only, residing at the Clinical Research Unit (CRU) from Day -1 (the day before dosing) to Day 13 (120 hours post the last dose).
This first part (Part 1) will test doses already evaluated in the previous single ascending dose study (F901318-01-01-14, 0.25-4 mg/kg given over 4 hours). The dose levels for the study are expected to be 1.5, 3 and 4 mg/kg/day given as a four hour infusion once daily.
In the second part of the study (Part 2), doses higher than those previously evaluated may be studied and/or different dosing schedules designed to deliver a maximum tolerated dose over 24 hours. If a dose level higher than those previously studied is chosen, there will be an optional single dose studied initially for safety and pharmacokinetic profile (Part 2A), followed about 14 days later in another group of subjects by exposure at that same dose level over 8 consecutive days (Part 2B). These higher doses may be given in a once or twice daily dosing schedule. Six subjects will receive active compound and two will receive placebo in both the single dose and multiple dose cohorts. The single dose cohorts will receive study drug in a sentinel group design in which two subjects receive study drug (one active and one placebo) on the first day and the rest of the group one day later. There will be a review of safety data by the Principal Investigator and the Medical Monitor after the first two subjects have been dosed and before the last six subjects are dosed in each cohort in part 2A.
In Part 2, up to forty-eight subjects will complete the study in up to 6 cohorts (Part 2A, Groups D1 to F1, single day dosing, and Part 2B, Groups D2 to F2 eight days' dosing). Subjects in Parts 1 and 2B will be on the study for approximately 7 weeks and Part 2A for approximately 8 weeks. Each subject will participate in one treatment cohort only, residing at the Clinical Research Unit (CRU) from Day -1 (the day before dosing) to Day 6 (120 hours after the single dose in Parts 1 and 2A) and from Day -1 (the day before dosing) to Day 13 (120 hours after the first dose in Part 2B). The proposed total daily dose levels for Part 2 will be up to 10 mg/kg/day given either once daily or in two split daily doses. The duration of the infusions will be between 2 and 24 hours which may include a loading dose to achieve therapeutic plasma concentrations as quickly as possible.
All subjects will return for a post-study visit 8 to 10 days after the last dose of study medication.
연구 유형
등록 (실제)
단계
- 1단계
연락처 및 위치
연구 장소
-
-
UK
-
London, UK, 영국, NW10 7EW
- Hammersmith Medicines Research
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Subjects will be males of any ethnic origin between 18 and 45 years of age and weighing 60-100 kg inclusive
- Subjects must be in good health, as determined by a medical history, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations (congenital non haemolytic hyperbilirubinaemia is acceptable)
- Subjects will have given their written informed consent to participate in the study and to abide by the study restrictions
- Subjects must have ophthalmology assessments within the normal limits at screening. This includes normal Meibomian gland function
Exclusion Criteria:
- Male subjects who are not willing to use appropriate contraception (such as a condom) during the study and until follow up
- Subjects who have received any prescribed systemic or topical medication within 14 days of dosing with study drug unless in the opinion of the Investigator and the Medical Monitor the medication will not interfere with the study procedures or compromise safety
- Subjects who have used any non-prescribed systemic or topical medication (including herbal remedies) within 7 days of dosing with study drug (with the exception of vitamin/mineral supplements and paracetamol) unless in the opinion of the Investigator and the Medical Monitor the medication will not interfere with the study procedures or compromise safety
- Subjects who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days of dosing with study drug unless in the opinion of the Investigator and the Medical Monitor the medication will not interfere with the study procedures or compromise safety
- Subjects who are still participating in a clinical study (e.g. attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical or biological entity) in the past 3 months since the last dose.
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
---|---|
실험적: A active
Six subjects receiving F901318 1.5 mg/kg intravenously for eight days
|
Administration of active compound
|
위약 비교기: A placebo
Two subjects receiving F901318 placebo intravenously for eight days
|
위약 투여
|
실험적: B active
Six subjects receiving F901318 3 mg/kg intravenously for eight days
|
Administration of active compound
|
위약 비교기: B placebo
Two subjects receiving F901318 placebo intravenously for eight days
|
위약 투여
|
실험적: C active
Six subjects receiving F901318 4 mg/kg intravenously for eight days
|
Administration of active compound
|
위약 비교기: C placebo
Two subjects receiving F901318 placebo intravenously for eight days
|
위약 투여
|
실험적: D1 active
Six subjects dosed for one day with F901318 intravenously dose to be determined
|
Administration of active compound
|
위약 비교기: D1 placebo
Two subjects receiving F901318 placebo intravenously for one day
|
위약 투여
|
실험적: E1 active
Six subjects dosed for one day with F901318 intravenously dose to be determined
|
Administration of active compound
|
위약 비교기: E1 placebo
Two subjects receiving F901318 placebo intravenously for one day
|
위약 투여
|
실험적: F1 active
Six subjects dosed for one day with F901318 intravenously dose to be determined
|
Administration of active compound
|
위약 비교기: F1 placebo
Two subjects receiving F901318 placebo intravenously for one day
|
위약 투여
|
실험적: D2 active
Six subjects dosed for eight days with F901318 intravenously dose to be determined
|
Administration of active compound
|
위약 비교기: D2 placebo
Two subjects receiving F901318 placebo intravenously for eight days
|
위약 투여
|
실험적: E2 active
Six subjects dosed for eight days with F901318 intravenously dose to be determined
|
Administration of active compound
|
위약 비교기: E2 placebo
Two subjects receiving F901318 placebo intravenously for eight days
|
위약 투여
|
실험적: F2 active
Six subjects dosed for eight days with F901318 intravenously dose to be determined
|
Administration of active compound
|
위약 비교기: F2 placebo
Two subjects receiving F901318 placebo intravenously for eight days
|
위약 투여
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
safety: adverse events
기간: 13 days
|
adverse events
|
13 days
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
---|---|---|
pharmacokinetics AUC
기간: 13 days
|
area under concentration time curve
|
13 days
|
pharmacokinetics Cmin
기간: 13 days
|
drug level in blood 24 hours after dosing
|
13 days
|
공동 작업자 및 조사자
스폰서
수사관
- 수석 연구원: Frans van den Berg, MB ChB, Hammersmith Medicines Research
연구 기록 날짜
연구 주요 날짜
연구 시작
기본 완료 (실제)
연구 완료 (실제)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (추정)
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .
침습성 아스페르길루스증에 대한 임상 시험
위약에 대한 임상 시험
-
AJU Pharm Co., Ltd.OM Pharma SA모병
-
University Hospital, Strasbourg, France모집하지 않고 적극적으로